DelveInsight’s, “Brain Metastasis from Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Brain Metastasis from the Breast Cancer pipeline landscape. It covers the Brain Metastasis from Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Brain Metastasis from Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Brain Metastasis from Breast Cancer Pipeline Report
- DelveInsight’s Brain Metastasis from Breast Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Brain Metastasis from Breast Cancer treatment.
- The leading companies working in the Brain Metastasis from Breast Cancer Market include Angiochem Inc, Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criterium Inc, Bristol-Myers Squibb, Bayer, Northwest Biotherapeutics, Array BioPharma, and others
- Promising Brain Metastasis from Breast Cancer Pipeline Therapies include Efaproxiral, NKTR-102, Eribulin, Ixabepilone, capecitabine, lapatinib, trastuzumab, and others
- October 2023: Medical University of Vienna announced a study of Phase 2 clinical trials for Datopotamab deruxtecan. Phase II Study of Datopotamab-Deruxtecan (Dato-DXd; DS-1026a) in Triple-negative Breast Cancer Patients with Newly Diagnosed or Progressing Brain Metastases.
- October 2023: Dana-Farber Cancer Institute announced a study of Phase 2 clinical trials for Capecitabine and Ado-Trastuzumab Emtansine. The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2).
Request a sample and discover the recent advances in Brain Metastasis from Breast Cancer Treatment Drugs @ Brain Metastasis from Breast Cancer Pipeline Report
In the Brain Metastasis from Breast Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Brain Metastasis from Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Brain Metastasis from Breast Cancer Overview
Central nervous system or brain metastases traditionally occur in 10-16% of metastatic breast cancer patients and are associated with a dismal prognosis. The development of brain metastases has been associated with young age, and tumors that are estrogen receptor negative, Her-2+ or of the basal phenotype. Diagnosis can be done through MRI (magnetic resonance imaging) study of the brain.
Find out more about Brain Metastasis from Breast Cancer Therapeutics Assessment @ Brain Metastasis from Breast Cancer Preclinical and Discovery Stage Products
Brain Metastasis from Breast Cancer Emerging Drugs Profile
- ANG1005: Angiochem
- Pembrolizumab: Merck Sharp & Dohme
Brain Metastasis from Breast Cancer Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Brain Metastasis from Breast Cancer. The Brain Metastasis from Breast Cancer companies which have their Brain Metastasis from Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Angiochem.
DelveInsight’s Brain Metastasis from Breast Cancer Pipeline Report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Brain Metastasis from Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
Brain Metastasis from Breast Cancer Pipeline Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Learn more about the emerging Brain Metastasis from Breast Cancer Pipeline Therapies @ Brain Metastasis from Breast Cancer Clinical Trials Assessment
Scope of the Brain Metastasis from Breast Cancer Pipeline Report
- Coverage- Global
- Brain Metastasis from Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Brain Metastasis from Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Brain Metastasis from Breast Cancer Companies- Angiochem Inc, Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criterium Inc, Bristol-Myers Squibb, Bayer, Northwest Biotherapeutics, Array BioPharma, and others
- Brain Metastasis from Breast Cancer Pipeline Therapies- Efaproxiral, NKTR-102, Eribulin, Ixabepilone, capecitabine, lapatinib, trastuzumab, and others.
Dive deep into rich insights for new drugs for Brain Metastasis from Breast Cancer Treatment, Visit @ Brain Metastasis from Breast Cancer Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Brain Metastasis from Breast Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- ANG1005: Angiochem
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Early stage products (Phase I)
- Pembrolizumab: Merck Sharp & Dohme
- Drug profiles in the detailed report…..
- Inactive Products
- Brain Metastasis from Breast Cancer Key Companies
- Brain Metastasis from Breast Cancer Key Products
- Brain Metastasis from Breast Cancer- Unmet Needs
- Brain Metastasis from Breast Cancer- Market Drivers and Barriers
- Brain Metastasis from Breast Cancer- Future Perspectives and Conclusion
- Brain Metastasis from Breast Cancer Analyst Views
- Brain Metastasis from Breast Cancer Key Companies
- Appendix
For further information on the Brain Metastasis from Breast Cancer Pipeline therapeutics, reach out to Brain Metastasis from Breast Cancer Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/liver-fibrosis-market
